Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04616573 · ClinicalTrials.gov registry record · NA
A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma
A NA study, sponsored by Sight Sciences.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT04616573: Clinical Trial NA study, sponsored by Sight Sciences.
NCT04616573 is a NA study that was terminated before completion, run by Sight Sciences. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04616573, a NA study, was terminated before completion, sponsored by Sight Sciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
To prospectively compare the clinical effect of the OMNI surgical system in eyes with Open Angle Glaucoma.
Primary Outcome
The trial was terminated early after randomization and treatment of one subject who was exited from the study after 1 week of follow up. No meaningful conclusions or results were obtained due to early termination after the treatment of one subject.
Interventions
- DEVICE OMNI® Surgical System
- DEVICE iStent inject
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-11-13 |
| Est. Completion | 2021-01-20 |
| Phase | NA |
Why NCT04616573 stopped before completion
NCT04616573 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which OMNI® Surgical System is the first listed.
NCT04616573 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04616573 about?
NCT04616573 is a clinical study titled "A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma". To prospectively compare the clinical effect of the OMNI surgical system in eyes with Open Angle Glaucoma.
What is the current status of trial NCT04616573?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2020-11-13. Estimated completion is 2021-01-20.
What interventions are being tested in trial NCT04616573?
The interventions under investigation include: OMNI® Surgical System (DEVICE), iStent inject (DEVICE).
Who is sponsoring clinical trial NCT04616573?
This trial is sponsored by Sight Sciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04616573's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI